TARA vs. PHAR, VALN, ORGO, CRMD, OPT, UPB, BCYC, IMTX, PRTA, and KURA
Should you be buying Protara Therapeutics stock or one of its competitors? The main competitors of Protara Therapeutics include Pharming Group (PHAR), Valneva (VALN), Organogenesis (ORGO), CorMedix (CRMD), Opthea (OPT), Upstream Bio (UPB), Bicycle Therapeutics (BCYC), Immatics (IMTX), Prothena (PRTA), and Kura Oncology (KURA). These companies are all part of the "pharmaceutical products" industry.
Protara Therapeutics vs.
Pharming Group (NASDAQ:PHAR) and Protara Therapeutics (NASDAQ:TARA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, community ranking, dividends, media sentiment, risk, valuation and institutional ownership.
Pharming Group has a beta of -0.08, suggesting that its share price is 108% less volatile than the S&P 500. Comparatively, Protara Therapeutics has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500.
0.0% of Pharming Group shares are held by institutional investors. Comparatively, 38.1% of Protara Therapeutics shares are held by institutional investors. 2.1% of Pharming Group shares are held by company insiders. Comparatively, 12.5% of Protara Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Protara Therapeutics has a net margin of 0.00% compared to Pharming Group's net margin of -6.09%. Pharming Group's return on equity of -7.65% beat Protara Therapeutics' return on equity.
Protara Therapeutics received 17 more outperform votes than Pharming Group when rated by MarketBeat users. Likewise, 68.97% of users gave Protara Therapeutics an outperform vote while only 67.65% of users gave Pharming Group an outperform vote.
Pharming Group presently has a consensus price target of $30.00, suggesting a potential upside of 249.65%. Protara Therapeutics has a consensus price target of $20.40, suggesting a potential upside of 396.35%. Given Protara Therapeutics' higher possible upside, analysts clearly believe Protara Therapeutics is more favorable than Pharming Group.
Pharming Group has higher revenue and earnings than Protara Therapeutics. Pharming Group is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Pharming Group had 3 more articles in the media than Protara Therapeutics. MarketBeat recorded 9 mentions for Pharming Group and 6 mentions for Protara Therapeutics. Pharming Group's average media sentiment score of 1.45 beat Protara Therapeutics' score of 0.07 indicating that Pharming Group is being referred to more favorably in the media.
Summary
Protara Therapeutics beats Pharming Group on 9 of the 16 factors compared between the two stocks.
Get Protara Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TARA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Protara Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:TARA) was last updated on 4/24/2025 by MarketBeat.com Staff
